It seems most drug-makers are making their biggest sales to doctors by pushing medicines for common conditions whether they be statins for cholesterol or proton pump inhibitors for heartburn. But drugs can actually take on blockbuster significance for specialized treatment groups where treatment options are limited. Jeffrey Aronin, president and CEO of Ovation Pharmaceuticals Inc. tells the Chicago Tribune's Bruce Japsen about his company's efforts to build blockbuster franchises by treating rare conditions.
ReachMD
Be part of the knowledge.™Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?
Finding & Developing Drugs for Rare Conditions
Share this program on:
Choose a format
Media formats available:
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Comments
Presenters
Recommended
Details
Presenters
Comments
Recommended
Overview
It seems most drug-makers are making their biggest sales to doctors by pushing medicines for common conditions whether they be statins for cholesterol or proton pump inhibitors for heartburn. But drugs can actually take on blockbuster significance for specialized treatment groups where treatment options are limited. Jeffrey Aronin, president and CEO of Ovation Pharmaceuticals Inc. tells the Chicago Tribune's Bruce Japsen about his company's efforts to build blockbuster franchises by treating rare conditions.
Presenters
Facebook Comments